---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-016374"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2025-06-25T23:59:59+00:00"
generated_at: "2026-05-18T19:09:59.058412+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nasdaq panel approves Dare Bioscience's compliance plan; deadline Aug 12, 2025

## Summary
- Panel approved modified plan to regain compliance with Nasdaq Listing Rules 5550(b)(1) (≥$2.5M equity) or 5550(b)(2) (≥$35M MVLS).
- Must demonstrate compliance by July 31, 2025; conditional listing ends August 12, 2025.
- If plan fails, Nasdaq may delist common stock before August 12, 2025.
- Company has been non-compliant with Rule 5550(b) since August 2024.
- No assurances given that compliance will be achieved by the deadlines.

## SEC filing metadata
- accession: 0001641172-25-016374
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2025-06-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000164117225016374/0001641172-25-016374-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000164117225016374/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-016374
- JSON: https://secwatch.observer/filing/0001641172-25-016374.json
- Plain text: https://secwatch.observer/filing/0001641172-25-016374.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.